Risa Labs
Overview
Risa Labs is a Palo Alto-based healthtech company specializing in oncology AI solutions. Founded in 2024 by Kshitij Jaggi and Kumar Shivang, alumni of IIT Kanpur, the company aims to revolutionize cancer care workflows with its Business Operating System as a Service (BOSS) platform. In April 2025, Risa Labs raised $3.5 million in seed funding, led by Flipkart co-founder Binny Bansal, with participation from other significant investors such as Oncology Ventures and General Catalyst. This funding is directed towards expanding BOSS across 100 cancer centers in the United States.
Recent Developments
- April 2025: Risa Labs raised $3.5 million in a seed funding round led by Binny Bansal, with the participation of Oncology Ventures, General Catalyst, z21 Ventures, Odd Bird VC, and angel investor Ashish Gupta. The newly raised capital will support the deployment of the BOSS platform across 100 cancer centers in the U.S. over the next two years.
- March 2025: The BOSS platform significantly reduced prior authorization times in a test setup from 30 minutes to under five minutes at a leading U.S. cancer center, processing over $1 million in medications and reducing administrative costs by 66%.
- February 2025: Risa Labs outlined its strategic plan to become the AI transformation partner across the oncology ecosystem, facilitating improved coordination among providers and stakeholders within the drug lifecycle.
- 2024: The development and initial testing phase showed BOSS's capacity to automate complex workflows, drastically cutting delays caused by prior authorization, a chronic challenge in cancer care.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2024 |
| Headquarters | Palo Alto, California, USA |
| Founders | Kshitij Jaggi, Kumar Shivang |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Binny Bansal, Oncology Ventures |
| Industry | Healthtech, AI in Oncology |
| Number of Employees | Approximately 27 |
Early History
Risa Labs was founded in 2024 by Kshitij Jaggi and Kumar Shivang following their previous venture in Urban Health. The founders identified inefficiencies in cancer care, particularly around prior authorization processes that delay critical treatments. Their venture, Risa Labs, was thus conceived to address these inefficiencies using AI-driven solutions. Drawing from their expertise and a successful track of innovating in healthcare technology, they designed the BOSS platform, aiming to simplify and speed up administrative tasks in oncology, thereby potentially saving lives through more timely treatments.
Company Profile and Achievements
Risa Labs operates within the healthtech sector, focusing on leveraging AI to optimize healthcare delivery. Their flagship product, BOSS, automates the complex workflow of prior authorizations in oncology, a task historically burdened by delays and administrative paperwork.
- 2025: Successful testing showed the platform's capacity to reduce task time drastically, achieving significant operational efficiencies at multiple cancer centers.
- The company’s business model involves a combination of upfront transformation fees and ongoing charges per process completion, ensuring alignment of their financial incentives with performance enhancement for cancer centers.
- Strategic Vision: Emphasizing scalability, the company plans to expand its AI-driven orchestration across the entire oncology ecosystem from treatment to drug lifecycle management.
Current Operations and Market Position
Risa Labs currently operates its AI platform extensively in oncology workflows. It seeks to improve market positions by reducing the time-consuming nature of prior authorizations, which has historically caused treatment delays. By positioning itself as an essential partner in the oncology ecosystem, Risa Labs enhances the efficiency of oncology operations, aligning them with the rapidly advancing therapeutic innovation landscape. It stands competitive due to its proprietary system capable of cutting down costly administrative processes and improving patient care timelines.
Conclusion
Risa Labs is at the forefront of integrating AI into healthcare, specifically focusing on oncology. Through its innovative BOSS platform, it has demonstrated the potential to revolutionize cancer care delivery by significantly reducing authorization delays that hinder the commencement of timely treatment. With the recent influx of substantial funding, Risa Labs is well-positioned to expand its influence within the U.S. cancer care landscape, fostering a seamless, efficient, and patient-centered healthcare environment. The company’s future will likely feature broader national and potentially international applications as it refines and scales its offerings to meet evolving healthcare demands.